High Incidence of Acute Kidney Injury in Patients Treated with High-Dose Amoxicillin and Cloxacillin Combination Therapy.
acute kidney injury
amoxicillin
cloxacillin
combination therapy
endocarditis
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 Jun 2022
04 Jun 2022
Historique:
received:
06
05
2022
revised:
27
05
2022
accepted:
02
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
High-dose amoxicillin and cloxacillin combination therapy is recommended for the empiric treatment of selected patients with infective endocarditis despite a low level of evidence. The main objective of this study was to evaluate the renal tolerance of high-dose intravenous amoxicillin and cloxacillin combination. We studied 27 patients treated with amoxicillin and cloxacillin (≥100 mg/kg daily) for at least 48 h. The primary endpoint was the occurrence of acute kidney injury (AKI). The median patient age was 68 ± 8 years, and 16 (59%) were male. The indication for this combination therapy was suspected or confirmed endocarditis with no bacterial identification in 22 (81%) patients. The primary endpoint occurred in 16 (59%) patients after initiating this combination therapy within an average of 4.4 ± 3.6 days. Among them, seven (26%) patients developed severe AKI, including four (15%) patients who required hemodialysis. Other risk factors for AKI were identified in all patients, including injection of iodinated contrast media in 21 (78%), acute heart failure in 18 (67%), cardiac surgery in 11 (41%), and aminoglycoside use in 9 (33%) patients. This study reports an incidence of 59% of AKI after initiating amoxicillin and cloxacillin combination therapy in a population at high renal risk.
Identifiants
pubmed: 35740176
pii: antibiotics11060770
doi: 10.3390/antibiotics11060770
pmc: PMC9220067
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antibiotics (Basel). 2021 Jan 20;10(2):
pubmed: 33498191
Kidney Int Rep. 2020 Dec 13;6(3):830-834
pubmed: 33732998
Open Forum Infect Dis. 2018 May 23;5(6):ofy123
pubmed: 29977970
Clin Infect Dis. 2021 May 4;72(9):e232-e239
pubmed: 32687184
Clin Microbiol Infect. 2020 Jun;26(6):723-728
pubmed: 31669426
J Clin Med. 2020 Jun 27;9(7):
pubmed: 32605085
J Am Coll Cardiol. 2017 Jan 24;69(3):325-344
pubmed: 28104075
Crit Care. 2013 Oct 04;17(5):R220
pubmed: 24093498
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
J Chemother. 2017 Oct;29(5):292-298
pubmed: 28245728
Eur J Intern Med. 2009 Jul;20(4):407-10
pubmed: 19524184
J Antimicrob Chemother. 2015;70(6):1738-43
pubmed: 25645208
J Clin Med. 2021 Jun 12;10(12):
pubmed: 34204743
Int J Antimicrob Agents. 2018 Sep;52(3):344-349
pubmed: 29665445
Nephrol Dial Transplant. 2021 Sep 27;36(10):1955-1958
pubmed: 33848352
Clin Infect Dis. 2022 May 01;:
pubmed: 35510938
Clin Nephrol. 1998 Feb;49(2):96-101
pubmed: 9524779
N Engl J Med. 2006 Aug 17;355(7):653-65
pubmed: 16914701
Clin Microbiol Infect. 2019 Jul;25(7):818-827
pubmed: 30928559